XIAP immunoreactivity in glial and neuronal cytoplasmic inclusions in multiple system atrophy

Clinical Neuropathology

Volumn 33, Issue 1, 2014, Pages 76-83

  Kawamoto, Yasuhiro ^a,b   Ito, Hidefumi ^c   Ihara, Masafumi ^d   Takahashi, Ryosuke ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Department of Neurology   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Glial cytoplasmic inclusions; HtrA2 Omi; Linked inhibitor of apoptosis protein; Multiple system atrophy; Neuronal cytoplasmic inclusions; X

Indexed keywords

ALPHA SYNUCLEIN; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CELL INCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE NUCLEUS; FEMALE; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFERIOR OLIVE; LOCUS CERULEUS; MALE; MIDDLE AGED; MOTONEURON NUCLEUS; NERVE CELL; NEURITE; OLIGODENDROGLIA; PONTINE NUCLEUS; PRIORITY JOURNAL; PURKINJE CELL; PUTAMEN; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; VAGUS NERVE; WHITE MATTER;

AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCLUSION BODIES; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MULTIPLE SYSTEM ATROPHY; NEUROGLIA; SERINE ENDOPEPTIDASES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84891657485     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300610     Document Type: Article

References (32)

1. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969; 32: 28-34. CrossRef PubMed
2. Wenning GK, Ben Shlomo Y, Magalhães M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994; 117: 835-845. CrossRef PubMed
3. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989; 94: 79-100. CrossRef PubMed
4. Nakazato Y, Yamazaki H, Hirato J, Ishida Y, Yamaguchi H. Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. J Neuropathol Exp Neurol. 1990; 49: 521-530. CrossRef PubMed
5. Jellinger KA, Lantos PL. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update. Acta Neuropathol. 2010; 119: 657-667. CrossRef PubMed
6. Kato S, Nakamura H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol. 1990; 79: 584-594. CrossRef PubMed
7. Arima K, Murayama S, Mukoyama M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Acta Neuropathol. 1992; 83: 453-460. CrossRef PubMed
8. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev. 1999; 13: 239-252. CrossRef PubMed
9. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997; 388: 300-304. CrossRef PubMed
10. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001; 6: 253-261. CrossRef PubMed
11. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, Reed JC. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998; 273: 7787-7790. CrossRef PubMed
12. Sun C, Cai M, Meadows RP, Xu N, Gunasekera AH, Herrmann J, Wu JC, Fesik SW. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem. 2000; 275: 33777-33781. CrossRef PubMed
13. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell. 2001; 8: 613-621. CrossRef PubMed
14. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes-Alnemri T, Alnemri ES. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem. 2002; 277: 432-438. CrossRef PubMed
15. Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, Savopoulos J, Gray CW, Creasy CL, Dingwall C, Downward J. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem. 2002; 277: 439-444. CrossRef PubMed
16. Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, Day CL, Tikoo A, Burke R, Wrobel C, Moritz RL, Simpson RJ, Vaux DL. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem. 2002; 277: 445-454. CrossRef PubMed
17. Kawamoto Y, Kobayashi Y, Suzuki Y, Inoue H, Tomimoto H, Akiguchi I, Budka H, Martins LM, Downward J, Takahashi R. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with a-synucleinopathies. J Neuropathol Exp Neurol. 2008; 67: 984-993. CrossRef PubMed
18. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol. 1993; 52: 183-191. CrossRef PubMed
19. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276: 2045-2047. CrossRef PubMed
20. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O. Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease. Nat Genet. 1998; 18: 106-108. CrossRef PubMed
21. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG. The new mutation, E46K, of a-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004; 55: 164-173. CrossRef PubMed
22. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. a-synuclein in Lewy bodies. Nature. 1997; 388: 839-840. Cross-Ref PubMed
23. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett. 1997; 239: 45-48. CrossRef PubMed
24. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H. Accumulation of a-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 1998; 96: 445-452. CrossRef PubMed
25. Gai WP, Power JHT, Blumbergs PC, Blessing WW. Multiple-system atrophy: a new a-synuclein disease? Lancet. 1998; 352: 547-548. CrossRef PubMed
26. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. a-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 1998; 249: 180-182. CrossRef PubMed
27. Spillantini MG, Goedert M. The a-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000; 920: 16-27. CrossRef PubMed
28. Kawamoto Y, Ito H, Ihara M, Takahashi R. Immunohistochemical localization of X-linked inhibitor of apoptosis protein in brainstem-type and cortical Lewy bodies. NeuroReport. 2012; 23: 162-167. CrossRef PubMed
29. Probst-Cousin S, Rickert CH, Schmid KW, Gullotta F. Cell death mechanisms in multiple system atrophy. J Neuropathol Exp Neurol. 1998; 57: 814-821. CrossRef PubMed
30. Jellinger KA, Stadelmann C. Mechanisms of cell death in neurodegenerative disorders. J Neural Transm Suppl. 2000; 59: 95-114. PubMed
31. Crocker SJ, Liston P, Anisman H, Lee CJ, Smith PD, Earl N, Thompson CS, Park DS, Korneluk RG, Robertson GS. Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice. Neurobiol Dis. 2003; 12: 150-161. CrossRef PubMed
32. Inoue H, Tsukita K, Iwasato T, Suzuki Y, Tomioka M, Tateno M, Nagao M, Kawata A, Saido TC, Miura M, Misawa H, Itohara S, Takahashi R. The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J. 2003; 22: 6665-6674. CrossRef PubMed